Ramsay Stattman Vela & Price Inc. Acquires 905 Shares of Johnson & Johnson (NYSE:JNJ)

Ramsay Stattman Vela & Price Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,716 shares of the company’s stock after buying an additional 905 shares during the period. Johnson & Johnson accounts for about 3.3% of Ramsay Stattman Vela & Price Inc.’s portfolio, making the stock its 7th largest holding. Ramsay Stattman Vela & Price Inc.’s holdings in Johnson & Johnson were worth $10,677,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Winslow Evans & Crocker Inc. boosted its holdings in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after buying an additional 69 shares during the period. Lathrop Investment Management Corp boosted its holdings in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after buying an additional 69 shares during the period. Reik & CO. LLC boosted its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after buying an additional 70 shares during the period. Delta Investment Management LLC boosted its holdings in shares of Johnson & Johnson by 1.0% during the 2nd quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after buying an additional 71 shares during the period. Finally, IFG Advisory LLC boosted its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock valued at $2,274,000 after purchasing an additional 71 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.

A number of research firms have issued reports on JNJ. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. Finally, Cantor Fitzgerald boosted their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $164.93.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is owned by corporate insiders.

JNJ stock opened at $146.36 on Friday. The company has a 50 day simple moving average of $145.51 and a 200 day simple moving average of $146.57. The stock has a market cap of $385.30 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.12 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is 46.54%.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Why are trading ranges significant?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.